Brent McLaurin, MD
Cardiovascular Disease · Anderson, SCNPI 1740266725
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 664 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 52 manufacturers reported payments, led by Abbott at 25.1% of the total. Reporting peaked in 2019 at $2,004 and has fallen 61.5% since, to $772 in 2025.
Across 664 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Novartis$1K
- Inari Medical, Inc.$932
- Amgen$798
- Boehringer Ingelheim$629
- Merck$567
- plus $4K from 46 others
Across 917 payments — averaging $1146.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$369K
- Abbott$280K
- Janssen Research & Development, LLC$176K
- CSL Behring$105K
- Biotronik Inc.$58K
- Boehringer Ingelheim International GmbH$36K
- plus $28K from 3 others
What the payments were for
- Food & beverage$10,72499%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,789 in reported general payments places this provider in the 85th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 697 | $554,475 |
| EntrestoSacubitril/Valsartan | 159 | $149,988 |
| XareltoRivaroxaban | 100 | $95,773 |
| Repatha SureclickEvolocumab | 102 | $82,940 |
| MultaqDronedarone Hcl | 25 | $47,101 |
| BrilintaTicagrelor | 61 | $34,249 |
| FarxigaDapagliflozin Propanediol | 20 | $20,097 |
| JardianceEmpagliflozin | 20 | $19,794 |
| Repatha SyringeEvolocumab | 17 | $19,594 |
| Diltiazem 12hr ErDiltiazem Hcl | 26 | $4,751 |
| EdarbiAzilsartan Medoxomil | 11 | $4,177 |
| ClopidogrelClopidogrel Bisulfate | 258 | $3,018 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 95 | $2,944 |
| Metoprolol Succinate | 264 | $2,651 |
| Atorvastatin Calcium | 211 | $2,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $193 | $554,475697 claims |
| NovartisEntresto | $1,257 | $149,988159 claims |
| Johnson & JohnsonXarelto | $375 | $95,773100 claims |
| AstraZenecaBrilinta, Farxiga | $448 | $54,34681 claims |
| Sanofi-aventis U.S. LLCMultaq | $168 | $47,10125 claims |
| Boehringer IngelheimJardiance | $629 | $19,79420 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $41 | $4,17711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Anderson
- Ricky HendersonAnderson$52K
- John MeehanAnderson$13K
- Natalie KelseyAnderson$11K
- John WendtAnderson$10K
- Paul JonesAnderson$9K
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.